SGLT2 inhibitor lowers serum uric acid through alteration of uric acid transport activity in renal tubule by increased glycosuria von Chino, Yukihiro, Samukawa, Yoshishige, Sakai, Soichi, Nakai, Yasuhiro, Yamaguchi, Jun-ichi, Nakanishi, Takeo, Tamai, Ikumi

Volltext

Mechanism-Based Pharmacokinetic–Pharmacodynamic Modeling of Luseogliflozin, a Sodium Glucose Co-transporter 2 Inhibitor, in Japanese Patients with Type 2 Diabetes Mellitus von Samukawa, Yoshishige, Mutoh, Masaru, Chen, Shi, Mizui, Nobuo

Volltext

Influence of Renal Function on the 52-Week Efficacy and Safety of the Sodium Glucose Cotransporter 2 Inhibitor Luseogliflozin in Japanese Patients with Type 2 Diabetes Mellitus von Haneda, Masakazu, MD, PhD, Seino, Yutaka, MD, PhD, Inagaki, Nobuya, MD, PhD, Kaku, Kohei, MD, PhD, Sasaki, Takashi, MD, PhD, Fukatsu, Atsushi, MD, PhD, Kakiuchi, Haruka, MPharm, Sato, Yuri, BPharm, Sakai, Soichi, BPharm, Samukawa, Yoshishige, BPharm

Volltext

Efficacy and Safety of the SGLT2 Inhibitor Luseogliflozin in Japanese Patients With Type 2 Diabetes Mellitus Stratified According to Baseline Body Mass Index: Pooled Analysis of Da... von Sakai, Soichi, Bachelor of Pharmacy, Kaku, Kohei, MD, PhD, Seino, Yutaka, MD, PhD, Inagaki, Nobuya, MD, PhD, Haneda, Masakazu, MD, PhD, Sasaki, Takashi, MD, PhD, Fukatsu, Atsushi, MD, PhD, Kakiuchi, Haruka, Master of Pharmacy, Samukawa, Yoshishige, Bachelor of Pharmacy

Volltext

The flavonoid Sudachitin regulates glucose metabolism via PDE inhibition von Hatanaka, Ryoko, Taguchi, Akihiko, Nagao, Yuko, Yorimoto, Kaito, Takesato, Akari, Masuda, Konosuke, Ono, Takao, Samukawa, Yoshishige, Tanizawa, Yukio, Ohta, Yasuharu

Volltext

Randomized, Controlled, Thorough QT/QTc Study Shows Absence of QT Prolongation with Luseogliflozin in Healthy Japanese Subjects von Kumagai, Yuji, Hasunuma, Tomoko, Sakai, Soichi, Ochiai, Hidekazu, Samukawa, Yoshishige

Volltext

Fifty-two-week long-term clinical study of luseogliflozin as monotherapy in Japanese patients with type 2 diabetes mellitus inadequately controlled with diet and exercise von Seino, Yutaka, Kaku, Kohei, Inagaki, Nobuya, Haneda, Masakazu, Sasaki, Takashi, Fukatsu, Atsushi, Ubukata, Michito, Sakai, Soichi, Samukawa, Yoshishige

Volltext

Safety, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Luseogliflozin Dosing in Healthy Japanese Males: A Randomized, Single-Blind, Placebo-Controlled Trial von Sasaki, Takashi, Seino, Yutaka, Fukatsu, Atsushi, Sakai, Soichi, Samukawa, Yoshishige

Volltext

Efficacy and safety of luseogliflozin added to various oral antidiabetic drugs in Japanese patients with type 2 diabetes mellitus von Seino, Yutaka, Inagaki, Nobuya, Haneda, Masakazu, Kaku, Kohei, Sasaki, Takashi, Fukatsu, Atsushi, Ubukata, Michito, Sakai, Soichi, Samukawa, Yoshishige

Volltext

Substantial Effects of Luseogliflozin Revealed by Analyzing Responses to Postprandial Hyperglycemia: Post Hoc Subanalyses of a Randomized Controlled Study von Samukawa, Yoshishige, Omiya, Hirohisa, Watase, Hirotaka, Nozaki, Kazunari, Sakai, Soichi, Nishimura, Rimei

Volltext

A Strategy for assessing potential drug-drug interactions of a concomitant agent against a drug absorbed via an intestinal transporter in humans von Mizuno-Yasuhira, Akiko, Nakai, Yasuhiro, Gunji, Emi, Uchida, Saeko, Takahashi, Teisuke, Kinoshita, Kohnosuke, Jingu, Shigeji, Sakai, Soichi, Samukawa, Yoshishige, Yamaguchi, Jun-Ichi

Volltext

Mechanism-Based Pharmacokinetic-Pharmacodynamic Modeling of Luseogliflozin, a Sodium Glucose Co-transporter 2 Inhibitor, in Japanese Patients with Type 2 Diabetes Mellitus von Yoshishige Samukawa, Masaru Mutoh, Shi Chen, Nobuo Mizui

Volltext

Efficacy and Safety of Lipase Inhibitor Orlistat in Japanese with Excessive Visceral Fat Accumulation: 24-Week, Double-Blind, Randomized, Placebo-Controlled Study von Shirai, Kohji, Fujita, Toru, Tanaka, Michitaka, Fujii, Yuka, Shimomasuda, Masatsugu, Sakai, Soichi, Samukawa, Yoshishige

Volltext

Fifty-two-week long-term clinical study of luseogliflozin as monotherapy in Japanese patients with type 2 diabetes mellitus inadequately controlled with diet and exercise von Yutaka Seino, Kohei Kaku, Nobuya Inagaki, Masakazu Haneda, Takashi Sasaki, Atsushi Fukatsu, Michito Ubukata, Soichi Sakai, Yoshishige Samukawa

Volltext

Impact of the lipase inhibitor orlistat on the human gut microbiota von Uehira, Yudai, Ueno, Hiroaki, Miyamoto, Junki, Kimura, Ikuo, Ishizawa, Yohei, Iijima, Hiroshi, Muroga, Shota, Fujita, Toru, Sakai, Soichi, Samukawa, Yoshishige, Tanaka, Yuri, Murayama, Shinya, Sakoda, Hideyuki, Nakazato, Masamitsu

Volltext

Reduction of Excessive Visceral Fat and Safety with 52-Week Administration of Lipase Inhibitor Orlistat in Japanese: Long-Term Clinical Study von Shirai, Kohji, Tanaka, Michitaka, Fujita, Toru, Fujii, Yuka, Shimomasuda, Masatsugu, Sakai, Soichi, Samukawa, Yoshishige

Volltext

Pharmacokinetics and Pharmacodynamics of Luseogliflozin, a Selective SGLT2 Inhibitor, in Japanese Patients With Type 2 Diabetes With Mild to Severe Renal Impairment von Samukawa, Yoshishige, Haneda, Masakazu, Seino, Yutaka, Sasaki, Takashi, Fukatsu, Atsushi, Kubo, Yusuke, Sato, Yuri, Sakai, Soichi

Volltext

Impact of Reduced Renal Function on the Glucose-Lowering Effects of Luseogliflozin, a Selective SGLT2 Inhibitor, Assessed by Continuous Glucose Monitoring in Japanese Patients with... von Jinnouchi, Hideaki, Nozaki, Kazunari, Watase, Hirotaka, Omiya, Hirohisa, Sakai, Soichi, Samukawa, Yoshishige

Volltext

Pharmacokinetics, Pharmacodynamics, and Safety of Luseogliflozin in Japanese Patients with Type 2 Diabetes Mellitus: A Randomized, Single-blind, Placebo-controlled Trial von Sasaki, Takashi, Seino, Yutaka, Fukatsu, Atsushi, Ubukata, Michito, Sakai, Soichi, Samukawa, Yoshishige

Volltext

SGLT2 inhibitor (Luseogliflozin): a new mechanism for treating type 2 diabetes mellitus and therapeutic potential to prevent the progression of diabetic complications von Kojima, Naoki, Samukawa, Yoshishige, Takahashi, Teisuke

Volltext